Matthew Cawson

Matthew Cawson

Auto-generated profile, based on publicly available information

Matthew Cawson

Terumo BCT Europe N.V., Zaventem, Belgium

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2014 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
MCMatthew Richard Cawson
Matthew Richard Cawson
SMStephen Andrew Mitchell
Stephen Andrew Mitchell
CKChris Knight
Chris Knight
HWHenry Wildey
Henry Wildey
DSDean Spurden
Dean Spurden
MOMichelle Elaine Orme
Michelle Elaine Orme
Background: An updated economic evaluation was conducted to compare the cost-effectiveness of the four tumour necrosis factor (TNF)-α inhibitors adalimumab, etanercept, golimumab and infliximab in active, progressive psoriatic arthritis (PsA) where response to standard treatment has been inadequate.Methods: A systematic review was conducted to identify relevant, recently published studies and the new trial data were synthesised, via a Bayesian network meta-analysis (NMA), to estimate the relative efficacy of the TNF-α inhibitors in terms of Psoriatic Arthritis Response Criteria (PsARC) response, Health Assessment Questionnaire (HAQ) scores and Psoriasis Area and Severity Index (PASI). A previously developed economic model was updated with the new meta-analysis results and current cost data. The model was adapted to delineate patients by PASI 50%, 75% and 90% response rates to differentiate between psoriasis outcomes.Results: All four licensed TNF-α inhibitors were significantly more effective than placebo in achieving PsARC response in patients with active PsA. Adalimumab, etanercept and infliximab were significantly more effective than placebo in improving HAQ scores in patients who had achieved a PsARC response and in improving HAQ scores in PsARC non-responders. In an analysis using 1,000 model simulations, on average etanercept was the most cost-effective treatment and, at the National Institute for Health and Care Excellence willingness-to-pay threshold of between £20,000 to £30,000, etanercept is the preferred option.Conclusions: The economic analysis agrees with the conclusions from the previous models, in that biologics are shown to be cost-effective for treating patients with active PsA compared with the conventional management strategy. In particular, etanercept is cost-effective compared with the other biologic treatments.

1 April 2018 in The Bone & Joint Journal
Verified
Journal Article
Open access
EHE. Hansson
E. Hansson
KHK. Hagberg
K. Hagberg
MCM. Cawson
M. Cawson
TBT. H. Brodtkorb
T. H. Brodtkorb
Aims: The aim of this study was to compare the cost-effectiveness of treatment with an osseointegrated percutaneous (OI-) prosthesis and a socket-suspended (S-) prosthesis for patients with a transfemoral amputation. Patients and Methods: A Markov model was developed to estimate the medical costs and changes in quality-adjusted life-years (QALYs) attributable to treatment of unilateral transfemoral amputation over a projected period of 20 years from a healthcare perspective. Data were collected alongside a prospective clinical study of 51 patients followed for two years. Results: OI-prostheses had an incremental cost per QALY gained of €83 374 compared with S-prostheses. The clinical improvement seen with OI-prostheses was reflected in QALYs gained. Results were most sensitive to the utility value for both treatment arms. The impact of an annual decline in utility values of 1%, 2%, and 3%, for patients with S-prostheses resulted in a cost per QALY gained of €37 020, €24 662, and €18 952, respectively, over 20 years. Conclusion: From a healthcare perspective, treatment with an OI-prosthesis results in improved quality of life at a relatively high cost compared with that for S-prosthesis. When patients treated with S-prostheses had a decline in quality of life over time, the cost per QALY gained by OI-prosthesis treatment was considerably reduced. Cite this article: Bone Joint J 2018;100-B:527–34.

1 November 2023 in Journal of Wound, Ostomy & Continence Nursing
Verified
Journal Article
Closed access
RBRichard R. W. Brady
Richard R. W. Brady
JSJulia Scott
Julia Scott
SGStephanie Grieveson
Stephanie Grieveson
MAMiriayi Aibibula
Miriayi Aibibula
MCMatthew Cawson
Matthew Cawson
EBEsben Bo Boisen
Esben Bo Boisen
PURPOSE: The purpose of this study was to evaluate clinical and economic outcomes during the first year following ostomy formation. DESIGN: Single-center retrospective audit. SUBJECTS AND SETTING: The sample comprised 200 patients who underwent surgery leading to ileostomy or colostomy at a large English National Health Service (NHS) Trust. METHODS: Clinical complications, medicine prescriptions, and interactions with healthcare services were reported over 12 months postsurgery, and interactions with the NHS were matched to the closest NHS unit cost to determine mean patient cost. RESULTS: The most common ostomy-related surgical site complications were high output (35.0%; n = 70), followed by moderate/severe peristomal skin complications (24.5%; n = 49) and bleeding (23.5%; n = 47). Ostomy management–related complications included general difficulties with ostomy management (50.0%; n = 100) and leakage-related mild peristomal skin issues (48.5%; n = 97). Clinical complication rates were highest in the first quarter following ostomy formation, except parastomal hernia, which increased in incidence over time. Ileostomy patients more frequently experienced high output, acute renal failure, and ostomy management–related complications and had increased length of inpatient admission. However, healthcare resource use was high in both groups, with a median of 13 inpatient admission days and 12 outpatient contacts overall within the first year. Mean cost per patient was £20,444.60 (US $26,018.41); 90.5% of these costs were attributed to ostomy-related factors. CONCLUSIONS: Patients are likely to experience at least one clinical complication following intestinal ostomy formation and have multiple interactions with the NHS. While a number of complications are more frequent in patients with ileostomies, both groups experienced considerable costs within the first year following surgery associated with ostomy management and recovery.

14 July 2023 in Journal of Medical Economics
Verified
Journal Article
Open access
FMFadoua El Moustaid
Fadoua El Moustaid
YNYoshino Nagai
Yoshino Nagai
DMDylan Mezzio
Dylan Mezzio
KHKeisuke Harada
Keisuke Harada
YPYi Piao
Yi Piao
TTToshibumi Taniguchi
Toshibumi Taniguchi
While global efforts have been made to prevent transmission of HIV, the epidemic persists. Men who have sex with men (MSM) are at high risk of infection. Despite evidence of its cost-effectiveness in other jurisdictions, pre-exposure prophylaxis (PrEP) for MSM is neither approved nor reimbursed in Japan. The cost-effectiveness analysis compared the use of once daily PrEP versus no PrEP among MSM over a 30-year time horizon from a national healthcare perspective. Epidemiological estimates for each of the 47 prefectures informed the model. Costs included HIV/AIDS treatment, HIV and testing for sexually transmitted infections, monitoring tests and consults, and hospitalization costs. Analyses included health and cost outcomes, as well as the incremental cost-effectiveness ratio (ICER) reported as the cost per quality-adjusted life year (QALY) for all of Japan and each prefecture. Sensitivity analyses were performed. The estimated proportion of HIV infections prevented with the use of PrEP ranged from 48% to 69% across Japan, over the time horizon. Cost savings due to lower monitoring costs and general medical costs were observed. Assuming 100% coverage, for Japan overall, daily use of PrEP costs less and was more effective; daily use of PrEP was cost-effective at a willingness to pay threshold of ¥5,000,000 per QALY in 32 of the 47 prefectures. Sensitivity analyses found that the ICER was most sensitive to the cost of PrEP. Compared to no PrEP use, once daily PrEP is a cost-effective strategy in Japanese MSM, reducing the clinical and economic burden associated with HIV.

3 April 2023 in Journal of Medical Economics
Verified
Journal Article
Open access
ALA. Looby
A. Looby
HDH. Davies
H. Davies
SMS. Mealing
S. Mealing
ASAdam Smith
Adam Smith
BAB. Avey
B. Avey
MCM. Cawson
M. Cawson
To generate utility decrements for three attributes associated with catheterisation for individuals with a spinal cord injury (SCI): the process of catheterisation, the physical impact of urinary t...

2 September 2025 in Transfusion and Apheresis Science
Verified
Journal Article
Open access
NANabih Azar
Nabih Azar
NCNelson J Chao
Nelson J Chao
MCManuel Cliquennois
Manuel Cliquennois
MGMaria Geske
Maria Geske
THTomoko Henzan
Tomoko Henzan
FWFranziska Waltl
Franziska Waltl
This study, conducted among collection and transplant centers in France, Germany, Japan, the United Kingdom (UK), and the United States (USA), aimed to better understand current trends, challenges, and future directions in cell collection and apheresis practices, focusing on the Spectra Optia™ Apheresis System. This cross-sectional study was conducted from July to November 2023 among facilities using the Spectra Optia™ Apheresis System, which could also be using other comparable cell collection technologies, with expertise in cell collection and therapeutics. Respondents completed an online questionnaire. Forty-four facilities (France: 9, Germany: 7, Japan: 7, UK: 6, USA: 15) consented to participate. Across participating centers, a marked trend towards autologous cell collections was evident in France (mean: 71 % of collections were for autologous purposes), Germany (74 %), UK (79 %), and USA (73 %). Among centers in Japan, a more balanced division between autologous (47 %) and allogeneic (53 %) collections was seen. Over half of all respondents indicated facing several key challenges, including issues related to supporting services, patients, logistics, purity, and technology. The respondents largely agreed that the cell therapy demand will increase over the next 3-5 years and estimated a growth of 10-200 %. This study highlights the breadth of indications for which Spectra Optia is used, and the dynamic nature and growth prospects of the field. Innovation and standardization in apheresis technologies will be important to drive the potential of cell-based therapeutics.